Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Benitec Biopharma (BNTC) Research & Development (2019 - 2025)

Benitec Biopharma has reported Research & Development over the past 7 years, most recently at $5.8 million for Q4 2025.

  • Quarterly results put Research & Development at $5.8 million for Q4 2025, up 1763.9% from a year ago — trailing twelve months through Dec 2025 was $18.6 million (up 86.11% YoY), and the annual figure for FY2025 was $18.3 million, up 17.45%.
  • Research & Development reached $5.8 million in Q4 2025 per BNTC's latest filing, up from $3.4 million in the prior quarter.
  • Across five years, Research & Development topped out at $6.5 million in Q1 2025 and bottomed at $313000.0 in Q4 2024.
  • Median Research & Development over the past 5 years was $3.2 million (2022), compared with a mean of $3.4 million.
  • The largest annual shift saw Research & Development plummeted 93.87% in 2024 before it surged 1763.9% in 2025.
  • Over 5 years, Research & Development stood at $3.1 million in 2021, then increased by 19.55% to $3.8 million in 2022, then surged by 35.66% to $5.1 million in 2023, then tumbled by 93.87% to $313000.0 in 2024, then soared by 1763.9% to $5.8 million in 2025.
  • Business Quant data shows Research & Development for BNTC at $5.8 million in Q4 2025, $3.4 million in Q3 2025, and $2.9 million in Q2 2025.